Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact for Clinical Use (SYMPACT-CP): a qualitative interview study
The SYMPACT-CP is valid to assess symptoms and impacts of PAH in clinical practice. Compared with the PAH-SYMPACT, it provides a consistent 7-day recall period for symptoms and impacts and may improve symptom monitoring and disease management during clinical appointments.
Authors
- Amélie Beaudet (ORCID: https://orcid.org/0000-0003-0535-672X)
- Leah Kleinman (ORCID: https://orcid.org/0000-0002-0632-9689)
- Stacy N. Davis (ORCID: https://orcid.org/0000-0003-4201-0891)
- Anne Skalicky (ORCID: https://orcid.org/0000-0001-9865-3824)
- Bjørn Bayer
Institutions
- Actelion (Switzerland) (CH)
Publication Details
- Journal
- BMC Pulmonary Medicine
- Published
- 2025-05-06
- DOI
- https://doi.org/10.1186/s12890-025-03681-2
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Janssen Pharmaceuticals